1.4M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Ian F. Smith | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 238,420 | 238,420 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director, Interim Executive Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 122,651 | 122,651 | - | - | Stock Option (Right to Buy) | |
| Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 89,000 | 89,000 | - | - | Employee Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2025 | 4,842 | 4,842 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 8,907 | 139,346 (0%) | 0% | 8.3 | 73,661 | Common Stock |
| Edward M. Kaye | Director | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 10,382 | 148,253 (0%) | 0% | 8.7 | 90,012 | Common Stock |
| Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 216,000 | 216,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 144,000 | 144,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 3,333 | 60,629 (0%) | 0% | 8.3 | 27,564 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 3,884 | 63,962 (0%) | 0% | 8.7 | 33,674 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 43,000 | 43,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 64,000 | 64,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 72,000 | 72,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 8.67 per share. | 18 Mar 2025 | 2,266 | 33,510 (0%) | 0% | 8.7 | 19,646 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 8.27 per share. | 18 Mar 2025 | 1,945 | 31,565 (0%) | 0% | 8.3 | 16,085 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2025 | 48,000 | 48,000 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 132,385 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 158,635 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 35,500 | 71,000 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 26,250 | 78,750 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 13,100 | 57,846 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 10,000 | 67,846 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 13,100 | 26,200 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,475 | 29,776 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 6,000 | 35,776 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,475 | 14,950 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 6,000 | 18,000 | - | - | Restricted Stock Units | |
| M. Kaye Edward | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 30 Dec 2024 | 35,000 | 96,885 (0%) | 0% | 0.6 | 21,000 | Common Stock |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 35,000 | 567,801 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 6,786 | 61,885 (0%) | 0% | 13.0 | 88,158 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 2,586 | 44,746 (0%) | 0% | 13.0 | 33,596 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 12.99 per share. | 09 Dec 2024 | 1,552 | 21,476 (0%) | 0% | 13.0 | 20,164 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.69 per share. | 09 Dec 2024 | 12,114 | 23,028 (0%) | 0% | 13.7 | 165,814 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 6,170 | 68,671 (0%) | 0% | 12.8 | 78,837 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 13,945 | 47,332 (0%) | 0% | 12.8 | 178,182 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 12.78 per share. | 06 Dec 2024 | 9,696 | 35,142 (0%) | 0% | 12.8 | 123,891 | Common Stock |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 26,250 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 52,500 | 52,500 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 26,250 | 74,841 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 20,000 | 20,000 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 10,000 | 10,000 | - | - | Performance Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 10,000 | 61,277 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 6,000 | 44,838 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2024 | 6,000 | 6,000 | - | - | Performance Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 12,000 | 12,000 | - | - | Performance Stock Units | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 4,317 | - | - | Restricted Stock Unit (RSU) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 21,591 | 48,591 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 48,792 | 11,981 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.07 per share. | 01 Dec 2024 | 10,000 | 51,277 (0%) | 0% | 12.1 | 120,698 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Dec 2024 | 10,000 | 61,277 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 48,792 | 51,277 (0%) | 0% | 0 | Common Stock | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 33,927 | 38,838 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2024 | 33,927 | 12,357 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.68 per share. | 01 Nov 2024 | 10,000 | 2,485 (0%) | 0% | 12.7 | 126,803 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Nov 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Oct 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 10,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 12.06 per share. | 01 Oct 2024 | 10,000 | 2,485 (0%) | 0% | 12.1 | 120,648 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 03 Sep 2024 | 9,400 | 3,085 (0%) | 0% | 14.9 | 140,236 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 10,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.41 per share. | 03 Sep 2024 | 600 | 2,485 (0%) | 0% | 15.4 | 9,245 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 03 Sep 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 14.58 per share. | 01 Aug 2024 | 10,000 | 2,485 (0%) | 0% | 14.6 | 145,843 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Aug 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Huw M. Nash | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.10 per share. | 02 Jul 2024 | 2,467 | 33 (0%) | 0% | 13.1 | 32,320 | Common Stock |
| Huw M. Nash | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.91 per share. | 02 Jul 2024 | 33 | 0 (0%) | 0% | 13.9 | 459 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.75 per share. | 01 Jul 2024 | 10,000 | 2,485 (0%) | 0% | 13.7 | 137,458 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Jul 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2024 | 10,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Ian F. Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 03 Jun 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 10,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.78 per share. | 03 Jun 2024 | 103 | 2,485 (0%) | 0% | 15.8 | 1,625 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 15.21 per share. | 03 Jun 2024 | 9,897 | 2,588 (0%) | 0% | 15.2 | 150,560 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.05 per share. | 20 May 2024 | 2,664 | 27,000 (0%) | 0% | 16.0 | 42,746 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.39 per share. | 20 May 2024 | 39,686 | 29,664 (0%) | 0% | 15.4 | 610,783 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 15.39 per share. | 20 May 2024 | 50,000 | 0 (0%) | 0% | 15.4 | 769,500 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 50,000 | 46,000 | - | - | Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 20 May 2024 | 50,000 | 50,000 (0%) | 0% | 0.4 | 20,000 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 8,599 | 25,801 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 15.04 per share. | 20 May 2024 | 8,599 | 2,598 (0%) | 0% | 15.0 | 129,327 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.07 per share. | 20 May 2024 | 8,599 | 11,197 (0%) | 0% | 7.1 | 60,795 | Common Stock |
| Thomas Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 396,200 | 396,200 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 May 2024 | 10,000 | 12,485 (0%) | 0% | 0.6 | 6,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 10,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 11.37 per share. | 01 May 2024 | 10,000 | 2,485 (0%) | 0% | 11.4 | 113,653 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 50,000 | 96,000 | - | - | Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 13.61 per share. | 01 Apr 2024 | 400 | 0 (0%) | 0% | 13.6 | 5,444 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 01 Apr 2024 | 60,929 | 400 (0%) | 0% | 13.2 | 805,768 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 01 Apr 2024 | 50,000 | 61,329 (0%) | 0% | 0.4 | 20,000 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 01 Apr 2024 | 9,426 | 2,485 (0%) | 0% | 13.2 | 124,684 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Apr 2024 | 442 | 11,911 (0%) | 0% | 0.6 | 265 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 442 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.81 per share. | 28 Mar 2024 | 100 | 2,598 (0%) | 0% | 13.8 | 1,381 | Common Stock |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 13.19 per share. | 28 Mar 2024 | 5,026 | 2,698 (0%) | 0% | 13.2 | 66,287 | Common Stock |
| Stephen J. Tulipano | Former CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Stephen J. Tulipano | Former CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 105,000 | 105,000 | - | - | Restricted Stock Units | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 159,000 | 159,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 24,000 | 24,000 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2024 | 36,000 | 36,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 24,862 (0%) | 0% | 0 | Common Stock | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 39,300 | - | - | Restricted Stock Units | |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 4,116 | 20,746 (0%) | 0% | 6.1 | 25,102 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 11,150 | 69,350 (0%) | 0% | 6.1 | 67,999 | Common Stock |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 80,500 (0%) | 0% | 0 | Common Stock | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 35,500 | 106,500 | - | - | Restricted Stock Units | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 39,300 | - | - | Restricted Stock Units | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 15,445 (0%) | 0% | 0 | Common Stock | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 4,116 | 11,329 (0%) | 0% | 6.1 | 25,102 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 39,300 | - | - | Restricted Stock Units | |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 4,116 | 11,469 (0%) | 0% | 6.1 | 25,102 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 13,100 | 15,585 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,475 | 22,425 | - | - | Restricted Stock Units | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,475 | 10,073 (0%) | 0% | 0 | Common Stock | |
| Jonathan Allan | GENERAL COUNSEL & CORP SEC | Sale of securities on an exchange or to another person at price $ 6.10 per share. | 15 Mar 2024 | 2,349 | 7,724 (0%) | 0% | 6.1 | 14,326 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 7.75 per share. | 01 Mar 2024 | 10,000 | 2,485 (0%) | 0% | 7.7 | 77,469 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Mar 2024 | 5,504 | 12,485 (0%) | 0% | 0.6 | 3,302 | Common Stock |
| Barry S. Ticho | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2024 | 5,504 | 80,442 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 31,739 | 0 | - | - | Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 13 Feb 2024 | 31,739 | 31,739 (0%) | 0% | 2.2 | 69,508 | Common Stock |
| S. Ticho Barry | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 4.80 per share. | 01 Feb 2024 | 10,000 | 6,981 (0%) | 0% | 4.8 | 47,991 | Common Stock |
| S. Barry Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.74 per share. | 02 Jan 2024 | 10,000 | 16,981 (0%) | 0% | 5.7 | 57,352 | Common Stock |
| Tulipano J. Stephen | CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 107,400 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | General Counsel & Corp Sec | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 121,100 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Kaye M. Edward | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 25,908 | 25,908 | - | - | Restricted Stock Unit (RSU) | |
| Allan Jonathan | General Counsel & Corp Sec | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Tulipano Stephen J. | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 60,773 | 60,773 | - | - | Restricted Stock Unit (RSU) | |
| Tulipano J. Stephen | CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 60,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| S. Barry Ticho | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,600 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Nash Huw M. | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 8,463 | 8,463 | - | - | Restricted Stock Unit (RSU) | |
| Kaye M. Edward | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 200,800 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Allan Jonathan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 46,284 | 46,284 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 107,400 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Barry Ticho S. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 60,773 | 60,773 | - | - | Restricted Stock Unit (RSU) | |
| Huw M. Nash | COO & CBO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,600 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 65,600 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Ticho S. Barry | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Dec 2023 | 60,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.60 per share. | 03 Jul 2023 | 15,000 | 25,895 (0%) | 0% | 10.6 | 158,973 | Common Stock |
| Jonathan Allan | General Counsel & Corp Sec | Sale of securities on an exchange or to another person at price $ 13.48 per share. | 21 Jun 2023 | 1,948 | 0 (0%) | 0% | 13.5 | 26,252 | Common Stock |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.13 per share. | 01 Jun 2023 | 15,000 | 40,895 (0%) | 0% | 11.1 | 166,964 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 04 May 2023 | 653 | 55,895 (0%) | 0% | 10 | 6,530 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 01 May 2023 | 5,513 | 81,245 (0%) | 0% | 10.0 | 55,134 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.14 per share. | 01 May 2023 | 24,697 | 56,548 (0%) | 0% | 10.1 | 250,366 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 01 May 2023 | 24,967 | 86,758 (0%) | 0% | 10.0 | 249,767 | Common Stock |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 52,400 | 52,400 | - | - | Restricted Stock Unit (RSU) | |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,600 | 78,600 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 213,000 | 213,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 142,000 | 142,000 | - | - | Restricted Stock Unit (RSU) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,600 | 78,600 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 52,400 | 52,400 | - | - | Restricted Stock Unit (RSU) | |
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 52,400 | 52,400 | - | - | Restricted Stock Unite (RSU) | |
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 78,600 | 78,600 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Allan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 29,900 | 29,900 | - | - | Restricted Stock Unit (RSU) | |
| Jonathan Allan | General Counsel & Corp Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 44,800 | 44,800 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 03 Feb 2023 | 9,235 | 111,725 (0%) | 0% | 10.0 | 92,491 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.03 per share. | 03 Feb 2023 | 3,763 | 120,960 (0%) | 0% | 10.0 | 37,745 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 31 Jan 2023 | 5,705 | 124,990 (0%) | 0% | 10.0 | 57,140 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 31 Jan 2023 | 267 | 124,723 (0%) | 0% | 10 | 2,670 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 31 Jan 2023 | 200 | 130,695 (0%) | 0% | 10 | 2,000 | Common Stock |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 02 Jun 2022 | 11,160 | 11,762 (0%) | 0% | 4.5 | 49,997 | Common Stock |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2022 | 11,160 | 168,837 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 15,000 | 622,801 | - | - | Employee Stock Option (right to buy) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 25 May 2022 | 15,000 | 25,000 (0%) | 0% | 0.6 | 9,000 | Common Stock |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 107,400 | 107,400 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 308,000 | 308,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 107,400 | 107,400 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 107,400 | 107,400 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 03 Jan 2022 | 3,800 | 3,800 (0%) | 0% | 2.2 | 8,322 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 22.47 per share. | 03 Jan 2022 | 1,497 | 2,303 (0%) | 0% | 22.5 | 33,633 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 3,800 | 86,822 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 24.07 per share. | 03 Jan 2022 | 200 | 0 (0%) | 0% | 24.1 | 4,814 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 23.40 per share. | 03 Jan 2022 | 2,103 | 200 (0%) | 0% | 23.4 | 49,219 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2021 | 5,700 | 102,022 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 24.83 per share. | 01 Oct 2021 | 5,700 | 0 (0%) | 0% | 24.8 | 141,506 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Oct 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Sep 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2021 | 5,700 | 107,722 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 26.00 per share. | 01 Sep 2021 | 5,700 | 0 (0%) | 0% | 26.0 | 148,223 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 28.87 per share. | 02 Aug 2021 | 5,700 | 0 (0%) | 0% | 28.9 | 164,554 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2021 | 5,700 | 113,422 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 02 Aug 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 33.55 per share. | 13 Jul 2021 | 3,300 | 130,895 (0%) | 0% | 33.6 | 110,726 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.68 per share. | 13 Jul 2021 | 39,866 | 134,195 (0%) | 0% | 32.7 | 1,302,929 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 33.33 per share. | 01 Jul 2021 | 5,700 | 0 (0%) | 0% | 33.3 | 189,987 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2021 | 5,700 | 119,122 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Jul 2021 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Garry E. Menzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 39.42 per share. | 01 Jun 2021 | 575 | 0 (0%) | 0% | 39.4 | 22,669 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 575 | 124,822 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Jun 2021 | 575 | 575 (0%) | 0% | 2.2 | 1,259 | Common Stock |
| Stephen J. Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 65,600 | 65,600 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 200,800 | 200,800 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 65,600 | 65,600 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2021 | 65,600 | 65,600 | - | - | Employee Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 1,842 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,776 | 0 | - | - | Director Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Sale of securities on an exchange or to another person at price $ 61.14 per share. | 01 Mar 2021 | 4,957 | 0 (0%) | 0% | 61.1 | 303,087 | Common Stock |
| Arthur A. Levin | Director | Sale of securities on an exchange or to another person at price $ 60.55 per share. | 01 Mar 2021 | 7,543 | 4,957 (0%) | 0% | 60.6 | 456,754 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Mar 2021 | 7,882 | 12,500 (0%) | 0% | 0.6 | 4,729 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 01 Mar 2021 | 2,776 | 2,776 (0%) | 0% | 0.4 | 1,110 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 01 Mar 2021 | 1,842 | 4,618 (0%) | 0% | 0.4 | 737 | Common Stock |
| Arthur A. Levin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 7,882 | 8,764 | - | - | Director Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 58.60 per share. | 22 Feb 2021 | 5,000 | 602 (0%) | 0% | 58.6 | 292,992 | Common Stock |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 5,000 | 179,997 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2021 | 25,000 | 184,997 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 22 Feb 2021 | 5,000 | 5,602 (0%) | 0% | 4.5 | 22,400 | Common Stock |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 22 Feb 2021 | 102 | 602 (0%) | 0% | 60 | 6,120 | Common Stock |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 59.29 per share. | 22 Feb 2021 | 9,696 | 704 (0%) | 0% | 59.3 | 574,842 | Common Stock |
| Stephen J. Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 58.67 per share. | 22 Feb 2021 | 15,202 | 10,400 (0%) | 0% | 58.7 | 891,942 | Common Stock |
| Stephen J. Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 22 Feb 2021 | 25,000 | 25,602 (0%) | 0% | 4.5 | 112,000 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Feb 2021 | 10,000 | 13,447 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 60.67 per share. | 19 Feb 2021 | 10,000 | 0 (0%) | 0% | 60.7 | 606,652 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 19 Feb 2021 | 10,000 | 10,000 (0%) | 0% | 2.2 | 21,900 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 57.12 per share. | 04 Jan 2021 | 32 | 0 (0%) | 0% | 57.1 | 1,828 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 60.51 per share. | 04 Jan 2021 | 200 | 32 (0%) | 0% | 60.5 | 12,102 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 59.85 per share. | 04 Jan 2021 | 1,800 | 232 (0%) | 0% | 59.8 | 107,724 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 57.66 per share. | 04 Jan 2021 | 1,500 | 4,232 (0%) | 0% | 57.7 | 86,494 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 59.02 per share. | 04 Jan 2021 | 2,200 | 2,032 (0%) | 0% | 59.0 | 129,837 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 5,700 | 125,397 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 04 Jan 2021 | 5,700 | 5,732 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 21 Dec 2020 | 1,365 | 174,767 (0%) | 0% | 2.2 | 2,989 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 1,365 | 84,400 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 58.02 per share. | 21 Dec 2020 | 286 | 173,767 (0%) | 0% | 58.0 | 16,593 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 59.00 per share. | 21 Dec 2020 | 365 | 173,402 (0%) | 0% | 59.0 | 21,534 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 56.76 per share. | 21 Dec 2020 | 714 | 174,053 (0%) | 0% | 56.8 | 40,527 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 19,806 | 5,194 (0%) | 0% | 60 | 1,188,360 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 5,194 | 0 (0%) | 0% | 60 | 311,640 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 41,985 | 180,386 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 8,015 | 0 (0%) | 0% | 60 | 480,900 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 17 Dec 2020 | 8,015 | 8,015 (0%) | 0% | 0.6 | 4,809 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 17 Dec 2020 | 41,985 | 0 (0%) | 0% | 60 | 2,519,100 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 17 Dec 2020 | 41,985 | 41,985 (0%) | 0% | 0.6 | 25,191 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2020 | 8,015 | 172,371 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Dec 2020 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 5,700 | 131,097 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 52.72 per share. | 01 Dec 2020 | 400 | 0 (0%) | 0% | 52.7 | 21,088 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 51.45 per share. | 01 Dec 2020 | 100 | 400 (0%) | 0% | 51.5 | 5,145 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 50.02 per share. | 01 Dec 2020 | 2,481 | 500 (0%) | 0% | 50.0 | 124,103 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 49.19 per share. | 01 Dec 2020 | 2,719 | 2,981 (0%) | 0% | 49.2 | 133,744 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 27 Nov 2020 | 12,152 | 25,000 (0%) | 0% | 50 | 607,600 | Common Stock |
| Edward M. Kaye | Director, CEO | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 25 Nov 2020 | 12,848 | 37,152 (0%) | 0% | 50 | 642,400 | Common Stock |
| Seth Harrison | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 39.00 per share. | 24 Nov 2020 | 375,000 | 17,161,713 (52%) | 1% | 39 | 14,625,000 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 47.61 per share. | 23 Nov 2020 | 210 | 0 (0%) | 0% | 47.6 | 9,998 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 46.85 per share. | 23 Nov 2020 | 5,294 | 210 (0%) | 0% | 46.8 | 248,009 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2020 | 20,000 | 23,447 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 45.08 per share. | 23 Nov 2020 | 4,300 | 15,700 (0%) | 0% | 45.1 | 193,838 | Common Stock |
| Arthur O. Tzianabos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 23 Nov 2020 | 20,000 | 20,000 (0%) | 0% | 2.2 | 43,800 | Common Stock |
| Arthur O. Tzianabos | Director | Sale of securities on an exchange or to another person at price $ 45.97 per share. | 23 Nov 2020 | 10,196 | 5,504 (0%) | 0% | 46.0 | 468,720 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 10 Nov 2020 | 50,000 | 0 (0%) | 0% | 45 | 2,250,000 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2020 | 13,414 | 136,797 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2020 | 36,586 | 222,371 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 10 Nov 2020 | 13,414 | 50,000 (0%) | 0% | 2.2 | 29,377 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 10 Nov 2020 | 36,586 | 36,586 (0%) | 0% | 0.6 | 21,952 | Common Stock |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 36.79 per share. | 02 Nov 2020 | 20,155 | 15,447 (0%) | 0% | 36.8 | 741,448 | Common Stock |
| Stephen Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 02 Nov 2020 | 1,732 | 2,334 (0%) | 0% | 4.5 | 7,759 | Common Stock |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 38.44 per share. | 02 Nov 2020 | 400 | 602 (0%) | 0% | 38.4 | 15,374 | Common Stock |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 37.86 per share. | 02 Nov 2020 | 14,445 | 1,002 (0%) | 0% | 37.9 | 546,909 | Common Stock |
| Stephen Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 02 Nov 2020 | 35,000 | 35,602 (0%) | 0% | 4.5 | 156,800 | Common Stock |
| Stephen Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 33,268 | 209,997 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 1,732 | 243,265 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 35,000 | 244,997 | - | - | Employee Stock Option (Right to Buy) | |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 41.97 per share. | 02 Nov 2020 | 5,216 | 602 (0%) | 0% | 42.0 | 218,910 | Common Stock |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 41.42 per share. | 02 Nov 2020 | 11,111 | 5,818 (0%) | 0% | 41.4 | 460,214 | Common Stock |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 40.03 per share. | 02 Nov 2020 | 16,941 | 16,929 (0%) | 0% | 40.0 | 678,086 | Common Stock |
| Stephen Tulipano | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.48 per share. | 02 Nov 2020 | 33,268 | 33,870 (0%) | 0% | 4.5 | 149,041 | Common Stock |
| Stephen Tulipano | CFO | Sale of securities on an exchange or to another person at price $ 39.84 per share. | 02 Nov 2020 | 1,732 | 602 (0%) | 0% | 39.8 | 68,998 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 5,700 | 150,211 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 37.98 per share. | 02 Nov 2020 | 2,536 | 0 (0%) | 0% | 38.0 | 96,325 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 36.59 per share. | 02 Nov 2020 | 3,164 | 2,536 (0%) | 0% | 36.6 | 115,785 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 02 Nov 2020 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 16 Oct 2020 | 5,851 | 13,500 (0%) | 0% | 40.0 | 234,042 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 1,503 | 70,386 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 30,497 | 96,069 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2020 | 5,851 | 126,566 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 38.42 per share. | 16 Oct 2020 | 7,225 | 13,500 (0%) | 0% | 38.4 | 277,586 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 37.64 per share. | 16 Oct 2020 | 24,775 | 20,725 (0%) | 0% | 37.6 | 932,578 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 16 Oct 2020 | 1,503 | 45,500 (0%) | 0% | 2.2 | 3,292 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 16 Oct 2020 | 30,497 | 43,997 (0%) | 0% | 0.6 | 18,298 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 16 Oct 2020 | 5,851 | 19,351 (0%) | 0% | 0.6 | 3,511 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2020 | 1,649 | 132,417 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 13 Oct 2020 | 1,649 | 15,149 (0%) | 0% | 0.6 | 989 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 13 Oct 2020 | 1,649 | 13,500 (0%) | 0% | 40 | 65,960 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 34.86 per share. | 01 Oct 2020 | 2,300 | 0 (0%) | 0% | 34.9 | 80,183 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Oct 2020 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 34.33 per share. | 01 Oct 2020 | 3,400 | 2,300 (0%) | 0% | 34.3 | 116,718 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 5,700 | 155,911 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 08 Sep 2020 | 30,718 | 30,718 (0%) | 0% | 2.2 | 67,272 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 17,201 | 161,611 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 30,718 | 178,812 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 Sep 2020 | 17,201 | 0 (0%) | 0% | 30 | 516,030 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 08 Sep 2020 | 17,201 | 17,201 (0%) | 0% | 2.2 | 37,670 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 08 Sep 2020 | 30,718 | 0 (0%) | 0% | 30 | 921,540 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 27.60 per share. | 01 Sep 2020 | 5,000 | 700 (0%) | 0% | 27.6 | 138,015 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 5,700 | 209,530 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 28.71 per share. | 01 Sep 2020 | 700 | 0 (0%) | 0% | 28.7 | 20,098 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Sep 2020 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 28 Aug 2020 | 2,081 | 0 (0%) | 0% | 30 | 62,430 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2020 | 2,081 | 215,230 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 28 Aug 2020 | 2,081 | 2,081 (0%) | 0% | 2.2 | 4,557 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 24.73 per share. | 03 Aug 2020 | 5,700 | 0 (0%) | 0% | 24.7 | 140,943 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 5,700 | 217,311 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 03 Aug 2020 | 5,700 | 5,700 (0%) | 0% | 2.2 | 12,483 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 25.06 per share. | 16 Jul 2020 | 1,900 | 0 (0%) | 0% | 25.1 | 47,614 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2020 | 1,900 | 223,011 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 16 Jul 2020 | 1,900 | 1,900 (0%) | 0% | 2.2 | 4,161 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 22.41 per share. | 07 Jul 2020 | 913 | 0 (0%) | 0% | 22.4 | 20,457 | Common Stock |
| Robin A. Walker | Chief Legal Officer, CCO & Sec | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 07 Jul 2020 | 941 | 0 (0%) | 0% | 22.5 | 21,173 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 23.15 per share. | 01 Jul 2020 | 3,800 | 0 (0%) | 0% | 23.1 | 87,968 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 3,800 | 224,911 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Jul 2020 | 3,800 | 3,800 (0%) | 0% | 2.2 | 8,322 | Common Stock |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Seth Harrison | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 29,555 | 29,555 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2020 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Jun 2020 | 2,107 | 2,107 (0%) | 0% | 2.2 | 4,614 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2020 | 2,107 | 228,711 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 27.48 per share. | 01 Jun 2020 | 500 | 0 (0%) | 0% | 27.5 | 13,742 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 27.08 per share. | 01 Jun 2020 | 1,607 | 500 (0%) | 0% | 27.1 | 43,521 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 01 Jun 2020 | 1,000 | 173,027 (0%) | 0% | 27.2 | 27,174 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2020 | 42,880 | 85,765 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2020 | 131,147 | 85,946 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.98 per share. | 01 Jun 2020 | 365 | 172,662 (0%) | 0% | 28.0 | 10,213 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Jun 2020 | 42,880 | 174,027 (0%) | 0% | 2.2 | 93,907 | Common Stock |
| Barry S. Ticho | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 01 Jun 2020 | 131,147 | 131,147 (0%) | 0% | 0.6 | 78,688 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2020 | 20,000 | 71,889 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 01 Jun 2020 | 20,000 | 33,500 (0%) | 0% | 2.2 | 43,800 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 25.82 per share. | 01 Jun 2020 | 10,895 | 22,605 (0%) | 0% | 25.8 | 281,314 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 26.91 per share. | 01 Jun 2020 | 7,875 | 14,730 (0%) | 0% | 26.9 | 211,921 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 27.48 per share. | 01 Jun 2020 | 1,230 | 13,500 (0%) | 0% | 27.5 | 33,802 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 22 May 2020 | 7,500 | 13,500 (0%) | 0% | 30 | 225,000 | Common Stock |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2020 | 7,500 | 134,066 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.60 per share. | 22 May 2020 | 7,500 | 21,000 (0%) | 0% | 0.6 | 4,500 | Common Stock |
| Stephen Tulipano | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Edward M. Kaye | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2020 | 197,000 | 197,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Barry S. Ticho | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2020 | 42,000 | 42,000 | - | - | Employee Stock Option (Right to Buy) | |
| Robin A. Walker | Chief Legal Officer, CCO & Sec | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2020 | 42,779 | 230,818 | - | - | Employee Stock Option (Right to Buy) | |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.19 per share. | 02 Mar 2020 | 42,779 | 49,103 (0%) | 0% | 2.2 | 93,686 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 25.66 per share. | 02 Mar 2020 | 33,148 | 15,995 (0%) | 0% | 25.7 | 850,697 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.40 per share. | 02 Mar 2020 | 6,324 | 6,324 (0%) | 0% | 0.4 | 2,530 | Common Stock |
| Huw M. Nash | COO & CBO | Sale of securities on an exchange or to another person at price $ 26.37 per share. | 02 Mar 2020 | 15,995 | 0 (0%) | 0% | 26.4 | 421,852 | Common Stock |
| Huw M. Nash | COO & CBO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2020 | 6,324 | 146,000 | - | - | Employee Stock Option (Right to Buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 6,000 | 149,066 | - | - | Employee Stock Option (right to buy) | |
| Gene Liau | EVP Research & Preclinical Dev | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2019 | 7,500 | 141,566 | - | - | Employee Stock Option (right to buy) | |
| Edward M. Kaye | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2019 | 50,000 | 647,801 | - | - | Employee Stock Option (right to buy) | |
| Robin A. Walker | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2019 | 84,800 | 84,800 | - | - | Employee Stock Option (Right to Buy) | |
| Arthur A. Levin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2019 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2019 | 29,555 | 29,555 | - | - | Director Stock Option (Right to Buy) | |
| Arthur O. Tzianabos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2019 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Jennifer C. Burstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2019 | 29,555 | 29,555 | - | - | Director Stock Option (Right to Buy) | |
| Adrian R. Krainer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2019 | 14,777 | 14,777 | - | - | Director Stock Option (Right to Buy) | |
| Samuel W. Hall | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2019 | 29,555 | 29,555 | - | - | Director Stock Option (Right to Buy) | |
| Seth L. Harrison | Director, Ten Percent Owner | 21 Jun 2019 | 7,617,746 | 12,597,914 (38%) | 24% | 0 | Common Stock | ||
| Seth L. Harrison | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 21 Jun 2019 | 1,388,889 | 16,786,713 (51%) | 4% | 18 | 25,000,002 | Common Stock |
| Seth L. Harrison | Director, Ten Percent Owner | 21 Jun 2019 | 4,980,168 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Seth L. Harrison | Director, Ten Percent Owner | 21 Jun 2019 | 2,799,910 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Seth L. Harrison | Director, Ten Percent Owner | 21 Jun 2019 | 7,617,746 | 0 | - | - | Series A-2 Convertible Preferred Stock | ||
| Seth L. Harrison | Director, Ten Percent Owner | 21 Jun 2019 | 4,980,168 | 4,980,168 (15%) | 15% | 0 | Common Stock | ||
| Seth L. Harrison | Director, Ten Percent Owner | 21 Jun 2019 | 2,799,910 | 15,397,824 (47%) | 8% | 0 | Common Stock |